STING1 and acute myeloid leukemia: In a prior study showing efficacy of STING agonists against murine syngeneic AML models, it was speculated that, in addition to the benefits of IFN produced by host cells, therapeutic benefit might also depend on conditioning of tumor vasculature by augmented levels of TNFα (24).